Hyperkalemia risk and treatment of heart failure

Heart Fail Clin. 2008 Oct;4(4):455-64. doi: 10.1016/j.hfc.2008.03.009.

Abstract

This article briefly reviews the participation of the kidney in heart failure and the renal consequences of the treatment, with special emphasis on the risk for hyperkalemia and its management in daily clinical practice.

Publication types

  • Review

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Hyperkalemia / chemically induced*
  • Hyperkalemia / etiology
  • Hyperkalemia / prevention & control
  • Kidney / physiopathology*
  • Kidney Diseases / physiopathology*
  • Renin-Angiotensin System / drug effects
  • Risk Assessment
  • Risk Factors

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors